# 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

> **NCT05063357** · PHASE1 · WITHDRAWN · sponsor: **Y-mAbs Therapeutics**

## Conditions studied

- DIPG

## Interventions

- **DRUG:** 131I-Omburtamab
- **DEVICE:** Convention Enhanced Delivery

## Key facts

- **NCT ID:** NCT05063357
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03
- **Primary completion:** 2026-03
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Corporate business decision. Not due to safety or efficacy concerns.
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063357, "131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05063357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*